Skip to content

Relay Therapeutics

US · RLAY #2273 by market cap Listed 2020
16.12 +0.21 +1.32%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 10 in the most recent period (2026/Q3).
  • Total institutional ownership fell 2.9 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
126.09% -2.92pp
Institutions
322 +10
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund58.62%
VC/PE Fund35.52%
Hedge Fund15.99%
Public Company14.84%
Individual/Insider1.61%
Private Company0.26%
Government Pension Fund0.25%
Sovereign Wealth Fund0.24%
Family Office/Trust0.19%

Top holders as of 2026-06-30

SB Investment Advisers (UK) Limited 12.63% · 27.90M sh
FMR 10.97% · 24.24M sh
SoftBank Group Corp. 9.91% · 21.90M sh
BlackRock 7.56% · 16.70M sh
Casdin Capital, LLC 7.26% · 16.04M sh
Perceptive Advisors LLC 6.38% · 14.11M sh
Commodore Capital LP 5.43% · 12.00M sh
T. Rowe Price Group, Inc. 4.36% · 9.62M sh
State Street Global Advisors 4.14% · 9.15M sh
Vanguard Capital Management, LLC 4.08% · 9.01M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 13 buys · 37 sells

NameRoleStake
Sanjiv Patel Chief Executive Officer 0.61%
Mark Murcko Founder & Independent Director 0.45%
Donald Bergstrom President of Research & Development 0.18%
Alexis Borisy Independent Chairperson 0.11%
Brian Adams Former Chief Legal Officer 0.10%
Peter Rahmer Chief Corporate Development Officer 0.10%
Thomas Catinazzo Chief Financial Officer 0.05%
Douglas Ingram Independent Director 0.01%
SoftBank Group Corp. -- --
Linda Hill Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-27 Donald Bergstrom President of Research & Development Open Market Disposition -2,252 $18.62
2026-10-27 Peter Rahmer Chief Corporate Development Officer Open Market Disposition -753 $18.62
2026-10-27 Thomas Catinazzo Chief Financial Officer Open Market Disposition -1,469 $18.62
2026-10-06 Sanjiv Patel Chief Executive Officer Automatic Disposition -48,199 $18.10
2026-10-05 Thomas Catinazzo Chief Financial Officer Automatic Disposition -17,717 $18.58–19.26
2026-09-07 Donald Bergstrom President of Research & Development Automatic Disposition -8,530 $18.97
2026-09-07 Sanjiv Patel Chief Executive Officer Automatic Disposition -48,199 $18.94
2026-09-07 Thomas Catinazzo Chief Financial Officer Automatic Disposition -17,717 $18.94
2026-08-25 Peter Rahmer Chief Corporate Development Officer Automatic Disposition -4,508 $20.03
2026-08-24 SoftBank Group Corp. -- Private Disposition -6,000,000 $19.40
2026-08-16 Sanjiv Patel Chief Executive Officer Automatic Disposition -48,199 $20.33
2026-08-13 Thomas Catinazzo Chief Financial Officer Automatic Disposition -17,717 $19.74
2026-08-03 Sekar Kathiresan Former Independent Director Intent to Sell (Form 144) -42,225 $19.57
2026-07-30 Sekar Kathiresan Former Independent Director Intent to Sell (Form 144) -30,000 $18.79
2026-07-27 Donald Bergstrom President of Research & Development Open Market Disposition -2,237 $18.61
2026-07-27 Peter Rahmer Chief Corporate Development Officer Open Market Disposition -748 $18.61
2026-07-27 Thomas Catinazzo Chief Financial Officer Open Market Disposition -1,459 $18.61
2026-07-20 Sekar Kathiresan Former Independent Director Intent to Sell (Form 144) -30,000 $19.81
2026-07-19 Sekar Kathiresan Former Independent Director Intent to Sell (Form 144) -66,055 $19.58
2026-07-06 Sanjiv Patel Chief Executive Officer Automatic Disposition -48,199 $19.58

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Relay Therapeutics discussion 0 comments

Add a comment